Arindam Dhar

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6189917/publications.pdf

Version: 2024-02-01

5 papers	359 citations	1937685 4 h-index	5 g-index
5	5	5	577 citing authors
all docs	docs citations	times ranked	

#	Article	IF	CITATIONS
1	Phase 1 Study of Molibresib (GSK525762), a Bromodomain and Extra-Terminal Domain Protein Inhibitor, in NUT Carcinoma and Other Solid Tumors. JNCI Cancer Spectrum, 2020, 4, pkz093.	2.9	126
2	An Anatomical Site and Genetic-Based Prognostic Model for Patients With Nuclear Protein in Testis (NUT) Midline Carcinoma: Analysis of 124 Patients. JNCI Cancer Spectrum, 2020, 4, pkz094.	2.9	114
3	Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors. Clinical Cancer Research, 2019, 25, 7331-7339.	7.0	110
4	Population pharmacokinetic modeling of molibresib and its active metabolites in patients with solid tumors: A semimechanistic autoinduction model. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 709-722.	2.5	7
5	Exposure–response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors. CPT: Pharmacometrics and Systems Pharmacology, 2021, , .	2.5	2